VIBATIV
Total Payments
$3.0M
Transactions
13,328
Doctors
3,385
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $107,540 | 887 | 405 |
| 2023 | $137,138 | 1,074 | 411 |
| 2022 | $86,967 | 1,220 | 440 |
| 2021 | $100,213 | 785 | 344 |
| 2018 | $992,378 | 3,449 | 1,310 |
| 2017 | $1.6M | 5,913 | 1,960 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 205 | 54.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $568,239 | 325 | 18.8% |
| Food and Beverage | $317,679 | 11,894 | 10.5% |
| Consulting Fee | $275,923 | 148 | 9.1% |
| Travel and Lodging | $142,640 | 330 | 4.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $54,392 | 34 | 1.8% |
| Space rental or facility fees (teaching hospital only) | $23,450 | 19 | 0.8% |
| Education | $1,756 | 373 | 0.1% |
Payments by Type
Research
$1.6M
205 transactions
General
$1.4M
13,123 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Protocol #0112 | Theravance Biopharma Inc. | $880,820 | 0 |
| Protocol #0112 | Theravance Biopharma, Inc. | $639,382 | 1 |
| A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis | Theravance Biopharma, Inc. | $28,805 | 0 |
| TELAVANCIN PEDIATRIC PK STUDY (AGES >3 MONTHS TO 17 YEARS) | Cumberland Pharmaceuticals, Inc. | $25,899 | 0 |
| Protocol #0112_09072018_07 | Theravance Biopharma, Inc. | $16,985 | 0 |
| Protocol #0112_09072018_02 | Theravance Biopharma, Inc. | $12,669 | 0 |
| Protocol #0112_09072018_05 | Theravance Biopharma, Inc. | $8,412 | 0 |
| Protocol #0112_09072018_12 | Theravance Biopharma, Inc. | $7,423 | 0 |
| Protocol #0112_09072018_09 | Theravance Biopharma, Inc. | $3,226 | 0 |
| Protocol #0112_09072018_03 | Theravance Biopharma, Inc. | $3,200 | 0 |
| Protocol #0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy | Theravance Biopharma, Inc. | $2,175 | 2 |
| Protocol #0112_09072018_10 | Theravance Biopharma, Inc. | $1,920 | 0 |
| Protocol #0112_09072018_01 | Theravance Biopharma, Inc. | $1,750 | 0 |
| Protocol #0112_09072018_11 | Theravance Biopharma, Inc. | $1,686 | 0 |
| Protocol #0112_09072018_08 | Theravance Biopharma, Inc. | $1,593 | 0 |
| Study 1151266 | Theravance Biopharma, Inc. | $1,560 | 0 |
| Protocol #0112_09202018 | Theravance Biopharma, Inc. | $812.50 | 1 |
| Protocol #0112_09072018_06 | Theravance Biopharma, Inc. | $750.00 | 0 |
| Open Label Study of the Pharmacokinetics of a Single Dose of Televancin in Pediatric Patients Subjects Aged 1 to 17 years | Theravance Biopharma, Inc. | $500.00 | 0 |
| Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 3 months to 17 years | Theravance Biopharma, Inc. | $500.00 | 0 |
Top Doctors Receiving Payments for VIBATIV — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Infectious Disease | Newark, NJ | $700.51 | 6 |
| Charles Rose | Infectious Disease | Lexington, KY | $697.33 | 37 |
| , MD | Infectious Disease | Glendora, CA | $690.84 | 20 |
| , AGACNP | Acute Care | Bedford, TX | $680.83 | 32 |
| , M.D | Infectious Disease | Wheeling, WV | $671.66 | 42 |
| , M.D. , M.P.H | Infectious Disease | Palm Desert, CA | $667.41 | 44 |
| , M D | Infectious Disease | Sterling Heights, MI | $661.01 | 4 |
| , M.D | Infectious Disease | Delray Beach, FL | $658.74 | 29 |
| , MD | Critical Care Medicine | Greenbrae, CA | $650.00 | 1 |
| , M.D | Infectious Disease | Detroit, MI | $647.89 | 3 |
| , MD | Infectious Disease | Sugar Land, TX | $646.95 | 29 |
| Tatiana Mouravskaia | — | South Orange, NJ | $635.06 | 4 |
| , MD | Infectious Disease | Detroit, MI | $631.79 | 3 |
| , M.D | Infectious Disease | Fort Worth, TX | $627.65 | 11 |
| , MD | Infectious Disease | Sugar Land, TX | $591.53 | 31 |
| , M.D | Infectious Disease | Stratford, CT | $591.14 | 22 |
| , D.O | Infectious Disease | Midlothian, VA | $589.57 | 23 |
| , MD | Infectious Disease | Suwanee, GA | $580.58 | 28 |
| , FNP | Family | Murrieta, CA | $575.61 | 26 |
| , M.D | Infectious Disease | Memphis, TN | $563.43 | 12 |
| , MD | Infectious Disease | Odessa, TX | $559.92 | 5 |
| , M.D | Infectious Disease | Fort Myers, FL | $558.22 | 23 |
| , DO | Infectious Disease | Richland, WA | $556.32 | 19 |
| , DO FACOI | Infectious Disease | Somers Point, NJ | $555.38 | 18 |
| , MD | Emergency Medicine | Bogart, GA | $555.30 | 8 |
Ad
Manufacturing Companies
- Theravance Biopharma Inc. $1.6M
- Theravance Biopharma, Inc. $992,378
- Cumberland Pharmaceuticals, Inc. $430,232
- Verity Pharmaceuticals Inc. $1,626
Product Information
- Type Drug
- Total Payments $3.0M
- Total Doctors 3,385
- Transactions 13,328
About VIBATIV
VIBATIV is a drug associated with $3.0M in payments to 3,385 healthcare providers, recorded across 13,328 transactions in the CMS Open Payments database. The primary manufacturer is Theravance Biopharma Inc..
Payment data is available from 2017 to 2024. In 2024, $107,540 was paid across 887 transactions to 405 doctors.
The most common payment nature for VIBATIV is "Unspecified" ($1.6M, 54.2% of total).
VIBATIV is associated with 20 research studies, including "Protocol #0112" ($880,820).